Register for our free email digests:
Purdue Pharma LP
Latest From Purdue Pharma LP
Janssen, Teva, Allergan, Endo, and Purdue – as well as several distributors – pursued in multistate investigation that follows individual AG inquiries and flurry of state, city, and county suits.
Opponents say including data from a small pediatric trial of Purdue's buprenorphine patch could give the impression the study was more robust than it actually was, while supporters say labeling should reflect any available data that can inform pediatric prescribing.
Advisory committees will discuss whether data from a 41-patient study should be added to Pediatric Use section of labeling for Purdue's buprenorphine product; agency's decision to convene expert panel even though a pediatric indication is not being considered grew out of criticism generated by approval of OxyContin for adolescents.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Controlled Release
- OTC, Consumer
- Drug Delivery
- Therapeutic Areas
- Infectious & Viral Diseases
- Neurology, Nervous System
- Purdue Frederick Co.-Purdue Pharma LP
- North America
- Parent & Subsidiaries
- Purdue Pharma LP
- Senior Management
Craig Landau, Pres. & CEO
Jean-Jacques Charhon, CFO
Saeed Motahari, SVP, Chief Commercial Officer
J. Alan Butcher, Head, Licensing & Bus. Dev.
Alan Dunton, MD, Head, R&D
- Contact Info
Purdue Pharma LP
Phone: (203) 588-8000
201 Tresser Blvd.
Stamford, CT 06901
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.